Date: 2015-06-25
Type of information: Construction of a production plant
Compound: Antibody Drug Conjugate (ADC) facility at the Le Mans site
Company: Novasep (France)
Therapeutic area: Technology - Services
Type agreement: construction of a production plant
Action mechanism:
Disease:
Details: * On June 25, 2015, Novasep announced it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The facility is planned to be commissioned in Q2 2016. It will provide contract manufacturing in batch sizes from a few milligrams to 600g to ADC drug developers during clinical trial and commercial development phases. Novasep’s €10M investment in clinical and commercial scale ADC conjugation is a natural extension to its existing CMO offering and leverages its unique purification technologies. Novasep’s new ADC facility, whose design is now complete, will be capable of producing ADCs in full compliance with the highest standards in quality, health, environmental and industrial safety.
Financial terms:
Latest news:
